StockNews.com Upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to “Buy”

StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a research note released on Monday morning.

ALNY has been the topic of several other reports. Wells Fargo & Company dropped their price target on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an equal weight rating on the stock in a research report on Friday, February 16th. Wolfe Research assumed coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. They set a peer perform rating on the stock. Citigroup decreased their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a buy rating for the company in a report on Friday, February 16th. Royal Bank of Canada reiterated an outperform rating and set a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, JPMorgan Chase & Co. lifted their target price on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a neutral rating in a research note on Thursday, February 1st. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus target price of $215.88.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $147.36 on Monday. The company’s fifty day moving average price is $150.21 and its two-hundred day moving average price is $165.76. The company has a market capitalization of $18.56 billion, a price-to-earnings ratio of -41.39 and a beta of 0.39. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to the consensus estimate of $439.38 million. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the business posted ($1.68) EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals will post -4.46 EPS for the current year.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC increased its stake in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares during the period. Commonwealth Equity Services LLC boosted its stake in Alnylam Pharmaceuticals by 32.3% during the 1st quarter. Commonwealth Equity Services LLC now owns 5,594 shares of the biopharmaceutical company’s stock valued at $836,000 after purchasing an additional 1,365 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Alnylam Pharmaceuticals by 36.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 35,822 shares of the biopharmaceutical company’s stock valued at $5,354,000 after purchasing an additional 9,662 shares during the period. Prestige Wealth Management Group LLC increased its position in shares of Alnylam Pharmaceuticals by 69.8% during the 1st quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 194 shares during the period. Finally, Yousif Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 9.7% in the 1st quarter. Yousif Capital Management LLC now owns 1,635 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 144 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.